Pfizer Inc
Change company Symbol lookup
Select an option...
PFE Pfizer Inc
DUNE Dune Acquisition Corp
METV Roundhill Ball Metaverse ETF
TBNK Territorial Bancorp Inc
BAC Bank of America Corp
ICD Independence Contract Drilling Inc
NOK Nokia Oyj
DM Desktop Metal Inc
COIN Coinbase Global Inc
SOFI SoFi Technologies Inc

Health Care : Pharmaceuticals | Large Cap Value
Company profile

Pfizer Inc. (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products. Its global portfolio includes medicines and vaccines. The Company offers therapeutic candidates in gastroenterology, dermatology, and cardiology, including etrasimod, an oral, selective sphingosine 1-phosphate (S1P) receptor modulator in development for a range of immuno-inflammatory diseases, including ulcerative colitis, Crohn’s Disease, atopic dermatitis, eosinophilic esophagitis, and alopecia areata. The Company works across markets to develop wellness, prevention, treatments and cures. It collaborates with healthcare providers, governments and local communities to support and provide access to healthcare. The Company's medicines and vaccines provide value for healthcare providers and patients, through treatment of diseases, improvements in health, wellness.

Day's Change
0.585 (1.15%)
B/A Size
Day's High
Day's Low

Today's volume of 15,180,754 shares is on pace to be much lighter than PFE's 10-day average volume of 26,793,045 shares.


Curaleaf raises $425 million in debt

9:02 am ET December 14, 2021 (MarketWatch)

Alliance Global Securities analyst Aaron Grey said Tuesday a $425 million debt deal by Curaleaf Holdings Inc. will result in cost savings of about $20 million from lower interest payments. Grey reiterated a buy rating on Curaleaf and said larger cannabis companies such as Curaleaf hold an advantage in the current environment. Curaleaf Holdings said late Monday it received commitments for a $425 million private placement of 8.0% senior secured notes due 2026. Curaleaf CEO Joseph Bayern said the offering ranks as the largest debt financing of any publicly-traded multi-state operator in the cannabis business. The credit facility will be used to refinance debt at a lower interest rate, he said. Seaport Global Securities LLC and Canaccord Genuity Corp. were placement agents for the notes in the U.S. and Canada. Shares of Curaleaf are down 23.7% in 2021, compared to a drop of 26.2% by the Cannabis ETF (THCX).

-Steve Gelsi


(END) Dow Jones Newswires

December 14, 2021 09:02 ET (14:02 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.